ERIC JONASCH to Disease Progression
This is a "connection" page, showing publications ERIC JONASCH has written about Disease Progression.
Connection Strength
0.396
-
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021 04; 17(4):245-261.
Score: 0.086
-
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014 Mar; 191(3):611-8.
Score: 0.053
-
Targeted therapy for locally advanced renal cell carcinoma. Target Oncol. 2010 Jun; 5(2):113-8.
Score: 0.042
-
Prognostic models: from the fates to the future. Cancer. 2009 May 15; 115(10):2028-30.
Score: 0.039
-
Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009 May 01; 115(9):1859-66.
Score: 0.039
-
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 11 25; 385(22):2036-2046.
Score: 0.023
-
Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020 09 15; 26(18):4970-4982.
Score: 0.021
-
Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386.
Score: 0.020
-
Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget. 2017 Jun 27; 8(26):42149-42158.
Score: 0.017
-
Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opin Pharmacother. 2015 Apr; 16(6):805-19.
Score: 0.015
-
Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
Score: 0.015
-
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013 Nov; 14(12):1233-42.
Score: 0.013
-
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer. 2013 Oct; 49(15):3169-75.
Score: 0.013